Imexpharm Corporation (HOSE:IMP)

Market Cap	6.71T
Revenue (ttm)	2.31T
Net Income (ttm)	309.16B
Shares Out	154.01M
EPS (ttm)	2,007.45
PE Ratio	21.72
Forward PE	n/a
Dividend	454.55 (1.08%)
Ex-Dividend Date	Jul 11, 2024

Volume	45,700
Average Volume	131,965
Open	43,000
Previous Close	42,900
Day's Range	43,000 - 44,050
52-Week Range	29,273 - 56,500
Beta	0.81
RSI	47.97
Earnings Date	Apr 18, 2025

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl...

• Industry: Pharmaceutical Preparations
• Founded: 1977
• Employees: 1,452
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 16.85%.